XML 41 R18.htm IDEA: XBRL DOCUMENT
v3.24.3

Segments of Business and Geographic Areas | 9 Months Ended
--- | ---
Sep. 29, 2024
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | Segments of business and geographic areas Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine and MedTech. Sales by segment of business
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $3,068 |  | 3,193 |  | (3.9) | % |  | $8,499 |  | 8,506 |  | (0.1) | %
International |  | 1,552 |  | 1,656 |  | (6.2) |  |  | 5,090 |  | 4,951 |  | 2.8 |
Worldwide |  | 4,621 |  | 4,849 |  | (4.7) |  |  | 13,590 |  | 13,457 |  | 1.0 |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 281 |  | 296 |  | (5.4) |  |  | 778 |  | 849 |  | (8.5) |
U.S. Exports |  | 27 |  | 38 |  | (28.9) |  |  | 89 |  | 112 |  | (20.5) |
International |  | 112 |  | 127 |  | (11.5) |  |  | 380 |  | 449 |  | (15.4) |
Worldwide |  | 419 |  | 461 |  | (9.1) |  |  | 1,246 |  | 1,410 |  | (11.6) |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 299 |  | 310 |  | (3.7) |  |  | 820 |  | 866 |  | (5.3) |
International |  | 218 |  | 319 |  | (31.8) |  |  | 787 |  | 829 |  | (5.1) |
Worldwide |  | 516 |  | 629 |  | (18.0) |  |  | 1,607 |  | 1,695 |  | (5.2) |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,770 |  | 1,912 |  | (7.5) |  |  | 5,021 |  | 5,180 |  | (3.1) |
International |  | 906 |  | 951 |  | (4.8) |  |  | 2,991 |  | 2,925 |  | 2.2 |
Worldwide |  | 2,676 |  | 2,864 |  | (6.6) |  |  | 8,012 |  | 8,105 |  | (1.2) |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 691 |  | 634 |  | 9.1 |  |  | 1,789 |  | 1,490 |  | 20.1 |
International |  | 316 |  | 258 |  | 22.6 |  |  | 932 |  | 747 |  | 24.7 |
Worldwide |  | 1,007 |  | 891 |  | 13.0 |  |  | 2,721 |  | 2,237 |  | 21.6 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1 |  | 2 |  | (45.6) |  | 3 |  | 9 |  | (66.8) |
International |  | 0 |  | 0 |  | — |  |  | 0 |  | 0 |  | —
Worldwide |  | 1 |  | 2 |  | (45.6) |  | 3 |  | 9 |  | (66.8) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 365 |  | 360 |  | 1.5 |  |  | 1,023 |  | 1,147 |  | (10.8) |
International |  | 471 |  | 500 |  | (5.7) |  |  | 1,599 |  | 2,420 |  | (33.9) |
Worldwide |  | 836 |  | 859 |  | (2.7) |  |  | 2,622 |  | 3,566 |  | (26.5) |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 0 |  | — |  |  | 0 |  | 0 |  | —
International |  | 1 |  | 41 |  | (97.7) |  |  | 198 |  | 1,073 |  | (81.6) |
Worldwide |  | 1 |  | 41 |  | (97.7) |  |  | 198 |  | 1,073 |  | (81.6) |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
U.S. |  | 8 |  | 9 |  | (15.8) |  |  | 24 |  | 26 |  | (10.0) |
International |  | 323 |  | 287 |  | 12.3 |  |  | 926 |  | 816 |  | 13.5 |
Worldwide |  | 330 |  | 297 |  | 11.5 |  |  | 950 |  | 843 |  | 12.7 |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 355 |  | 345 |  | 2.8 |  |  | 990 |  | 1,105 |  | (10.5) |
International |  | 94 |  | 102 |  | (6.9) |  |  | 315 |  | 310 |  | 1.8 |
Worldwide |  | 449 |  | 447 |  | 0.6 |  |  | 1,305 |  | 1,415 |  | (7.8) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  | 5 |  | (52.2) |  |  | 10 |  | 15 |  | (37.7) |
International |  | 53 |  | 69 |  | (23.2) |  |  | 160 |  | 220 |  | (27.4) |
Worldwide |  | 55 |  | 74 |  | (25.4) |  |  | 169 |  | 235 |  | (28.0) |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,094 |  | 1,036 |  | 5.6 |  |  | 3,250 |  | 3,043 |  | 6.8 |
International |  | 662 |  | 706 |  | (6.2) |  |  | 2,090 |  | 2,296 |  | (8.9) |
Worldwide |  | 1,755 |  | 1,742 |  | 0.8 |  |  | 5,340 |  | 5,339 |  | 0.0
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 26 |  | 57 |  | (55.0) |  |  | 101 |  | 191 |  | (47.5) |
International |  | 117 |  | 133 |  | (11.9) |  |  | 382 |  | 412 |  | (7.3) |
Worldwide |  | 142 |  | 189 |  | (24.8) |  |  | 482 |  | 603 |  | (20.0) |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 780 |  | 730 |  | 6.8 |  |  | 2,329 |  | 2,164 |  | 7.6 |
International |  | 269 |  | 299 |  | (10.1) |  |  | 830 |  | 940 |  | (11.7) |
Worldwide |  | 1,049 |  | 1,029 |  | 1.9 |  |  | 3,159 |  | 3,104 |  | 1.8 |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 243 |  | 154 |  | 56.8 |  |  | 660 |  | 409 |  | 61.2 |
International |  | 42 |  | 29 |  | 44.6 |  |  | 120 |  | 74 |  | 62.9 |
Worldwide |  | 284 |  | 183 |  | 54.9 |  |  | 780 |  | 483 |  | 61.5 |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 46 |  | 94 |  | (51.4) |  |  | 161 |  | 278 |  | (42.1) |
International |  | 235 |  | 245 |  | (4.4) |  |  | 759 |  | 870 |  | (12.8) |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
Worldwide |  | 281 |  | 340 |  | (17.4) |  |  | 920 |  | 1,149 |  | (19.9) |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,816 |  | 2,219 |  | 26.9 |  |  | 7,835 |  | 6,177 |  | 26.8 |
International |  | 2,565 |  | 2,313 |  | 10.9 |  |  | 7,450 |  | 6,865 |  | 8.5 |
Worldwide |  | 5,380 |  | 4,533 |  | 18.7 |  |  | 15,284 |  | 13,043 |  | 17.2 |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 258 |  | 140 |  | 84.9 |  |  | 565 |  | 324 |  | 74.6 |
International |  | 27 |  | 12 |  | * |  | 63 |  | 17 |  | *
Worldwide |  | 286 |  | 152 |  | 87.7 |  |  | 629 |  | 341 |  | 84.3 |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,684 |  | 1,369 |  | 23.0 |  |  | 4,789 |  | 3,882 |  | 23.4 |
International |  | 1,332 |  | 1,130 |  | 17.9 |  |  | 3,797 |  | 3,312 |  | 14.6 |
Worldwide |  | 3,016 |  | 2,499 |  | 20.7 |  |  | 8,586 |  | 7,194 |  | 19.3 |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 337 |  | 288 |  | 17.1 |  |  | 940 |  | 778 |  | 20.8 |
International |  | 453 |  | 342 |  | 32.4 |  |  | 1,275 |  | 961 |  | 32.6 |
Worldwide |  | 790 |  | 631 |  | 25.4 |  |  | 2,215 |  | 1,740 |  | 27.3 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 259 |  | 264 |  | (1.9) |  |  | 770 |  | 796 |  | (3.2) |
International |  | 494 |  | 545 |  | (9.2) |  |  | 1,537 |  | 1,681 |  | (8.5) |
Worldwide |  | 753 |  | 808 |  | (6.8) |  |  | 2,307 |  | 2,476 |  | (6.8) |
TECVAYLI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 105 |  | 93 |  | 13.5 |  |  | 310 |  | 232 |  | 34.0 |
International |  | 30 |  | 19 |  | 54.2 |  |  | 93 |  | 37 |  | *
Worldwide |  | 135 |  | 112 |  | 20.6 |  |  | 403 |  | 269 |  | 49.6 |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 5 |  | 16 |  | (66.0) |  |  | 25 |  | 41 |  | (38.0) |
International |  | 144 |  | 199 |  | (27.1) |  |  | 470 |  | 646 |  | (27.1) |
Worldwide |  | 150 |  | 214 |  | (30.0) |  |  | 496 |  | 686 |  | (27.8) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 168 |  | 50 |  | * |  | 435 |  | 125 |  | *
International |  | 83 |  | 67 |  | 24.8 |  |  | 214 |  | 211 |  | 2.0 |
Worldwide |  | 250 |  | 117 |  | * |  | 649 |  | 336 |  | 93.4 |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 815 |  | 680 |  | 20.0 |  |  | 2,324 |  | 1,964 |  | 18.4 |
International |  | 287 |  | 274 |  | 4.5 |  |  | 866 |  | 835 |  | 3.7 |
Worldwide |  | 1,102 |  | 954 |  | 15.6 |  |  | 3,190 |  | 2,798 |  | 14.0 |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  | 323 |  | 25.4 |  |  | 1,135 |  | 924 |  | 22.8 |
International |  | 165 |  | 166 |  | (0.2) |  |  | 504 |  | 512 |  | (1.6) |
Worldwide |  | 571 |  | 490 |  | 16.8 |  |  | 1,639 |  | 1,437 |  | 14.1 |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
U.S. |  | 379 |  | 336 |  | 12.7 |  |  | 1,120 |  | 978 |  | 14.5 |
International |  | 80 |  | 66 |  | 21.8 |  |  | 232 |  | 185 |  | 25.5 |
Worldwide |  | 458 |  | 402 |  | 14.2 |  |  | 1,352 |  | 1,163 |  | 16.3 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 32 |  | 20 |  | 54.0 |  |  | 70 |  | 61 |  | 14.0 |
International |  | 40 |  | 42 |  | (3.9) |  |  | 129 |  | 137 |  | (5.8) |
Worldwide |  | 72 |  | 63 |  | 15.0 |  |  | 199 |  | 199 |  | 0.3 |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 713 |  | 763 |  | (6.5) |  |  | 2,061 |  | 2,254 |  | (8.5) |
International |  | 170 |  | 194 |  | (11.9) |  |  | 543 |  | 580 |  | (6.4) |
Worldwide |  | 884 |  | 957 |  | (7.6) |  |  | 2,605 |  | 2,834 |  | (8.1) |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 592 |  | 625 |  | (5.2) |  |  | 1,697 |  | 1,840 |  | (7.8) |
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 592 |  | 625 |  | (5.2) |  |  | 1,697 |  | 1,840 |  | (7.8) |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 121 |  | 139 |  | (12.2) |  |  | 364 |  | 414 |  | (11.9) |
International |  | 170 |  | 194 |  | (11.9) |  |  | 543 |  | 580 |  | (6.4) |
Worldwide |  | 292 |  | 332 |  | (12.0) |  |  | 908 |  | 994 |  | (8.7) |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8,871 |  | 8,249 |  | 7.5 |  |  | 24,993 |  | 23,090 |  | 8.2 |
International |  | 5,709 |  | 5,644 |  | 1.2 |  |  | 17,639 |  | 17,947 |  | (1.7) |
Worldwide |  | 14,580 |  | 13,893 |  | 4.9 |  |  | 42,632 |  | 41,037 |  | 3.9 |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,148 |  | 891 |  | 28.6 |  |  | 3,292 |  | 2,662 |  | 23.6 |
International |  | 819 |  | 667 |  | 22.8 |  |  | 2,353 |  | 2,019 |  | 16.5 |
Worldwide |  | 1,966 |  | 1,558 |  | 26.2 |  |  | 5,645 |  | 4,681 |  | 20.6 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 660 |  | 611 |  | 7.9 |  |  | 2,057 |  | 1,791 |  | 14.8 |
International |  | 619 |  | 549 |  | 12.7 |  |  | 1,889 |  | 1,658 |  | 14.0 |
Worldwide |  | 1,279 |  | 1,161 |  | 10.2 |  |  | 3,946 |  | 3,449 |  | 14.4 |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 293 |  | 254 |  | 15.4 |  |  | 905 |  | 790 |  | 14.5 |
International |  | 68 |  | 57 |  | 20.1 |  |  | 207 |  | 176 |  | 17.7 |
Worldwide |  | 362 |  | 311 |  | 16.3 |  |  | 1,112 |  | 966 |  | 15.1 |
SHOCKWAVE(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 163 |  | — |  | * |  | 240 |  | — |  | *
International |  | 66 |  | — |  | * |  | 66 |  | — |  | *
Worldwide |  | 229 |  | — |  | * |  | 306 |  | — |  | *
OTHER CARDIOVASCULAR(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  | 26 |  | 16.7 |  |  | 89 |  | 81 |  | 10.6 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
International |  | 66 |  | 61 |  | 7.7 |  |  | 192 |  | 186 |  | 3.0 |
Worldwide |  | 96 |  | 87 |  | 10.4 |  |  | 281 |  | 267 |  | 5.3 |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,359 |  | 1,349 |  | 0.7 |  |  | 4,229 |  | 4,100 |  | 3.2 |
International |  | 832 |  | 815 |  | 2.0 |  |  | 2,614 |  | 2,574 |  | 1.5 |
Worldwide |  | 2,191 |  | 2,164 |  | 1.2 |  |  | 6,843 |  | 6,674 |  | 2.5 |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 250 |  | 239 |  | 4.8 |  |  | 785 |  | 730 |  | 7.5 |
International |  | 131 |  | 136 |  | (3.6) |  |  | 435 |  | 432 |  | 0.6 |
Worldwide |  | 381 |  | 375 |  | 1.7 |  |  | 1,220 |  | 1,162 |  | 5.0 |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 212 |  | 207 |  | 2.2 |  |  | 684 |  | 654 |  | 4.5 |
International |  | 140 |  | 131 |  | 6.9 |  |  | 463 |  | 415 |  | 11.5 |
Worldwide |  | 352 |  | 338 |  | 4.0 |  |  | 1,147 |  | 1,069 |  | 7.2 |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 497 |  | 488 |  | 1.8 |  |  | 1,499 |  | 1,462 |  | 2.5 |
International |  | 265 |  | 253 |  | 4.2 |  |  | 786 |  | 775 |  | 1.4 |
Worldwide |  | 761 |  | 742 |  | 2.6 |  |  | 2,285 |  | 2,238 |  | 2.1 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 400 |  | 415 |  | (3.6) |  |  | 1,262 |  | 1,254 |  | 0.6 |
International |  | 296 |  | 295 |  | 0.4 |  |  | 930 |  | 952 |  | (2.3) |
Worldwide |  | 696 |  | 710 |  | (1.9) |  |  | 2,191 |  | 2,205 |  | (0.6) |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 983 |  | 994 |  | (1.1) |  |  | 2,965 |  | 2,984 |  | (0.6) |
International |  | 1,451 |  | 1,483 |  | (2.2) |  |  | 4,373 |  | 4,522 |  | (3.3) |
Worldwide |  | 2,434 |  | 2,479 |  | (1.8) |  |  | 7,338 |  | 7,507 |  | (2.2) |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 448 |  | 455 |  | (1.4) |  |  | 1,360 |  | 1,365 |  | (0.4) |
International |  | 661 |  | 709 |  | (6.8) |  |  | 1,977 |  | 2,139 |  | (7.6) |
Worldwide |  | 1,109 |  | 1,164 |  | (4.7) |  |  | 3,337 |  | 3,504 |  | (4.8) |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 535 |  | 540 |  | (0.9) |  |  | 1,605 |  | 1,619 |  | (0.9) |
International |  | 791 |  | 775 |  | 2.1 |  |  | 2,397 |  | 2,383 |  | 0.6 |
Worldwide |  | 1,325 |  | 1,314 |  | 0.8 |  |  | 4,001 |  | 4,002 |  | 0.0
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 549 |  | 512 |  | 7.2 |  |  | 1,619 |  | 1,599 |  | 1.3 |
International |  | 751 |  | 744 |  | 0.9 |  |  | 2,224 |  | 2,265 |  | (1.8) |
Worldwide |  | 1,300 |  | 1,256 |  | 3.5 |  |  | 3,843 |  | 3,864 |  | (0.5) |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 441 |  | 399 |  | 10.2 |  |  | 1,288 |  | 1,252 |  | 2.8 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
International |  | 527 |  | 529 |  | (0.3) |  |  | 1,508 |  | 1,568 |  | (3.8) |
Worldwide |  | 968 |  | 928 |  | 4.2 |  |  | 2,796 |  | 2,820 |  | (0.9) |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 108 |  | 112 |  | (3.6) |  |  | 331 |  | 346 |  | (4.4) |
International |  | 225 |  | 216 |  | 3.9 |  |  | 717 |  | 698 |  | 2.7 |
Worldwide |  | 333 |  | 328 |  | 1.3 |  |  | 1,048 |  | 1,044 |  | 0.3 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,038 |  | 3,747 |  | 7.8 |  |  | 12,105 |  | 11,345 |  | 6.7 |
International |  | 3,853 |  | 3,711 |  | 3.9 |  |  | 11,564 |  | 11,382 |  | 1.6 |
Worldwide |  | 7,891 |  | 7,458 |  | 5.8 |  |  | 23,669 |  | 22,727 |  | 4.1 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12,909 |  | 11,996 |  | 7.6 |  |  | 37,098 |  | 34,435 |  | 7.7 |
International |  | 9,562 |  | 9,355 |  | 2.2 |  |  | 29,203 |  | 29,329 |  | (0.4) |
Worldwide |  | $22,471 |  | 21,351 |  | 5.2 | % |  | $66,301 |  | 63,764 |  | 4.0 | %
* Percentage greater than 100% or not meaningful (1) Previously referred to as Interventional Solutions (2) Acquired on May 31, 2024 Earnings before provision for taxes by segment
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended |
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  |  |  |  |
Innovative Medicine(1) |  | $4,482 |  | 4,794 |  | (6.5) | % |  | $14,910 |  | 14,008 |  | 6.4 | % |  |  |  |  |
MedTech(2) |  | 1,059 |  | 1,185 |  | (10.6) |  |  | 3,668 |  | 4,265 |  | (14.0) |  |  |  |  |  |
Segment earnings before provision for taxes |  | 5,541 |  | 5,979 |  | (7.3) |  |  | 18,578 |  | 18,273 |  | 1.7 |  |  |  |  |  |
Less: Expense not allocated to segments (3) |  | 2,203 |  | 762 |  |  |  | 5,778 |  | 8,037 |  |  |  |  |  |  |
Worldwide income (loss) before tax |  | $3,338 |  | 5,217 |  | (36.0) | % |  | $12,800 |  | 10,236 |  | 25.0 | % |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.7 billion in both the fiscal third quarter of 2024 and 2023. Intangible amortization expense of $2.1 billion and $2.2 billion in the fiscal nine months of 2024 and 2023, respectively. •Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in the fiscal third quarter and fiscal nine months of 2024. •One-time COVID-19 Vaccine related exit costs of $0.1 billion and $0.7 billion in the fiscal nine months of 2024 and 2023, respectively. •Monetization of royalty rights of $0.3 billion in the fiscal third quarter and fiscal nine months of 2024. •A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. A restructuring related charge of $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively. Refer to Note 12 for additional details. •An In-process research and development impairment of $0.2 billion in the fiscal nine months of 2024 and $0.2 billion in the fiscal third quarter and fiscal nine months of 2023 associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. •Unfavorable changes in the fair value of securities of $0.4 billion and $0.5 billion in the fiscal third quarter and fiscal nine months of 2023, respectively. •Litigation expense of $0.4 billion in both the fiscal third quarter and fiscal nine months of 2024, primarily related to Risperdal Gynecomastia. Favorable litigation related items of $0.1 billion in the fiscal nine months of 2023. (2) MedTech includes: •Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal third quarter of 2024 and 2023, respectively. Intangible amortization expense of $1.3 billion and $1.1 billion in the fiscal nine months of 2024 and 2023, respectively. •Acquisition and integration related expense of $0.3 billion and $0.9 billion, primarily driven by the Shockwave acquisition, in the fiscal third quarter and fiscal nine months of 2024, respectively. Acquisition and integration related expense of $0.1 billion in the fiscal nine months of 2023. •A gain of $0.2 billion related to the Acclarent divestiture is included in the fiscal nine months of 2024. •A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. A restructuring related charge of $0.2 billion in the fiscal third quarter and fiscal nine months of 2023, respectively. (3) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal third quarter of 2024 includes charges for talc matters of $2.0 billion. The fiscal nine months of 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively (See Note 11, Legal Proceedings, for additional details). The fiscal nine months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal third quarter and fiscal nine months of 2023 include $0.6 billion related to the unfavorable change in the fair value of Kenvue shares. Sales by geographic area
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change |  | September 29, 2024 |  | October 1, 2023 |  | Percent Change
United States |  | $12,909 |  | 11,996 |  | 7.6 | % |  | $37,098 |  | 34,435 |  | 7.7 | %
Europe |  | 4,914 |  | 4,727 |  | 4.0 |  |  | 15,291 |  | 15,448 |  | (1.0) |
Western Hemisphere, excluding U.S. |  | 1,173 |  | 1,171 |  | 0.3 |  |  | 3,579 |  | 3,383 |  | 5.8 |
Asia-Pacific, Africa |  | 3,475 |  | 3,457 |  | 0.5 |  |  | 10,333 |  | 10,498 |  | (1.6) |
Total |  | $22,471 |  | 21,351 |  | 5.2 | % |  | $66,301 |  | 63,764 |  | 4.0 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration